DNA strand

Superior Diagnostic Methods for Cervical Cancer Detection

At CC Diagnostics, we harness the power of medical advancements to improve the detection of cervical cancer. Our PCR-based reagent kit provides accurate and timely results, ensuring early intervention and better outcomes for patients.

Learn MoreContact Us

Detect Cancer Early with epigenetic DNA analysis

Our cutting-edge technology allows for the early detection of cervical cancer, providing patients with a higher chance of successful treatment. With our innovative approach, we are able to identify abnormalities at the earliest stage, ensuring timely intervention and improved outcomes.

Cervical cancer cases go undetected
144,000
False positives lead to unnecessary treatment.
1.4 million
Most common cancer in women
4th

CC Diagnostics

Empowering women through optimal cervical cancer screening performance, availability and comfort.

At CC Diagnostics, we believe that early detection is key to improving patient outcomes. Our innovative medical advances are revolutionizing cervical cancer detection, providing accurate and timely results that can save lives.

Methica CC

Current Issues

Cervical cancer is the 4th most common cancer in women that leads to high morbidity and mortality. There is a global inequity in access to screening and treatment.

Almost 30% Missed Cancers

Each 4-week delay in diagnosis results in a 10% increase in mortality, significantly affecting womens health in a negative and clinically meaningful way.

Painful & Uncomfortable

Current participation of targeted women in cervical cancer screenings is only at 15% due to global inequities and associated emotional and physical barriers.

Long & Laborious Process

Current protocol requires multiple samples and works counterproductively. Most currently used screening and triage techniques are not compatible with automation.

Our Solution

Methica CC Kit

Revolutionary screening technology detecting cervical cancer early using novel epigenetic markers.

Order here
Of cases detected using CC Diagnostics superior technology
97%
More sensitive than Pap smear
21%
Times less hands on time of lab-technicians.
6X
Methica Kit

Featured News

Clinical Study

Presenting our achievements on EUROGIN 2025 in Porto

👩‍🔬 Putting science into practice, strategic collaborations and learning from experts during our EUROGIN 2025 visit in Porto. Our Chief Scientific Officer Jolien de Waard shared the scientific highlights of our work during two great presentations. With 1600+ international participants from 78 different countries this is the platform to share our clinical validation data and let the world know about our Methica CC kit superior performance. The feedback is well received and we’re very excited about the follow-up and implementation projects. 

Accelerator

CC Diagnostics enters EIT Health Catapult Semifinals

🎉We’re thrilled to announce that CC Diagnostics was selected as one of 30 trailblazing European start-ups in the prestigious EIT Catapult! With this program's support, we’re more energized than ever to advance cervical cancer screening and make a global impact on women’s healthcare.

Clinical Study

CC Diagnostics Completes Methica CC Clinical Validation Study with Groundbreaking Results

CC Diagnostics has successfully completed a large clinical validation study using samples from the Dutch National Screening Program. The results? 97% sensitivity for cancer detection, outperforming the pap smear by 21%—all without compromising specificity. This study, conducted across multiple centers, reflects real-world performance and eliminates bias, marking a significant leap forward in cervical cancer diagnostics.

Client Feedback

5 out of 5 stars